Prospective observational study to assess the feasibility and safety of appropriate <i>Plasmodium vivax</i> radical cure with tafenoquine or primaquine after quantitative G6PD testing during pilot implementation in Thailand.

ABSTRACT:

Introduction

Plasmodium vivax recurrence prevention using tafenoquine or primaquine is critical for achieving Thailand's malaria elimination targets. Both drugs may cause haemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. This study evaluated the operational feasibility and safety of administering tafenoquine or primaquine after quantitative G6PD point-of-care testing in Thailand.

Methods

This prospective, observational, multicentre, longitudinal study was conducted between 23 May 2022 and 14 September 2023 during pilot implementation at seven sites in Yala and Mae Hong Son provinces. Eligible patients were ≥16 years old with uncomplicated P. vivax malaria. G6PD enzyme activity was quantified using a point-of-care device. All patients

SUBMITTER: Sudathip P 

PROVIDER: S-EPMC12035454 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature